| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
29,385 |
24,404 |
$2.36M |
| 92134 |
|
49,881 |
46,106 |
$969K |
| J0178 |
Injection, aflibercept, 1 mg |
8,646 |
8,037 |
$935K |
| J2778 |
Injection, ranibizumab, 0.1 mg |
4,072 |
3,746 |
$456K |
| J9035 |
Injection, bevacizumab, 10 mg |
6,237 |
6,032 |
$131K |
| 92250 |
|
2,369 |
2,265 |
$100K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
9,006 |
8,387 |
$68K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
414 |
406 |
$22K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
71 |
68 |
$19K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
683 |
658 |
$13K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
423 |
414 |
$12K |
| 67228 |
|
15 |
14 |
$6K |
| 92201 |
|
137 |
133 |
$2K |
| 76512 |
|
17 |
13 |
$834.13 |
| 92235 |
|
24 |
24 |
$676.36 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
24 |
24 |
$447.25 |
| J7999 |
Compounded drug, not otherwise classified |
152 |
127 |
$0.00 |
| C9257 |
Injection, bevacizumab, 0.25 mg |
576 |
553 |
$0.00 |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
13 |
13 |
$0.00 |